Table 2. Summary of the aCGH and in situ PLAGL1 and p21 proteins expression data from primary liver tumors.
| Sample | Diagnostic | aCGH | Immunohistochemistry | |
|---|---|---|---|---|
| PLAGL1 Logratio | PLAGL1 | p21 | ||
| H001 | HCC | 0.000 | − | − |
| H002 | HCC | NA | + | − |
| H003 | HCC | 0.000 | + | − |
| H004 | HCC | NA | +++ | ++ |
| H005 | HCC | -0.472 | + | − |
| H012 | HCC | 0.000 | ++ | + |
| H013 | HCC | NA | ++ | + |
| H008 | FNH | -0.422 | + | − |
| H009 | CCC | 0.000 | ++ | + |
| H010 | HAC | -0.605 | ++ | ++ |
| H011 | HAC | NA | +++ | − |
| H015 | Normal tissue | NA | +++ | +++ |
The expression of PLAGL1 and p21 was evaluated in eleven tumor samples and one from normal liver tissue. Except two tumors, all exhibited lower level of PLAGL1, while expression of p21 in all of them was absent or lower than in normal liver tissue. HCC: hepatocellular carcinoma; FNH: focal nodular hyperplasia; CCC: cholangiocellular carcinoma; HAC: Hepatoadenocarcinoma. Negative values of the logratios indicate losses of genetic material, 0.000 means absense of genomic abnormalities and NA stands for not analyzed. Score of each marker was calculated as described in Materials and Methods: strong expression (+++), moderate expression (++), weak expression (+) and negative expression (−).